
Daily Derm Times: February 13, 2025
Key Takeaways
- Urticaria subtypes and emerging therapies, including dupilumab and remibrutinib, are explored for improved treatment strategies.
- Tailored approaches for atopic dermatitis management emphasize balancing biologics and corticosteroids.
Catch up on dermatology news, highlights, and insights from the past 24 hours.
To stay up-to-date with the latest dermatology news, sign up to receive our
The Complex World of Urticaria: Insights from Jason Hawkes, MD, MS
Hawkes discusses urticaria subtypes, treatments, and emerging therapies like dupilumab and remibrutinib.
Balancing Biologics and Corticosteroids: Tailored Approaches for Managing Atopic Dermatitis
Alexandra Golant, MD, led a Dermatology Times Case-Based Roundtable® event that focused on advancing therapeutic strategies for atopic dermatitis.
POLL: Looking Ahead to Winter Clinical Hawaii 2025
Are you attending Winter Clinical Hawaii? Answer our poll below to let us know.
New Study Examines Connection Between Formulation and Benzene Levels in BPO Products
Barbieri et al evaluated product use, benzoyl peroxide concentration, days until expiration, and more.
Allergan Medical Institute to Launch 3 New US Training Centers for Clinicians
The state-of-the-art facilities in California, Georgia, and Texas will expand AMI’s curriculum to providers of all levels.
The Dermatology Industry Landscape: Unpacking Mergers and Acquisitions and Other Economic Movements
Explore 2025’s dermatology M&A trends, economic shifts, and key investment drivers shaping the industry's future.
Revolutionizing Telemedicine in Dermatological Care
Renata Block, MMS, PA-C, and Michael Rubio, PA-C discuss the complexities of developing a telehealth program in the world of dermatology.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















